Background: Endothelin (ET)-1 contributes to raising blood pressure (BP) and inducing cardiovascular disease by vasoconstriction and potent stimulation of aldosterone secretion. In the rat this latter effect occurs via ET receptors; in humans in vitro studies implicated
E ndothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension a , a a a 1 . Introduction decreased endothelial ET -mediated NO production at-B tributable to impaired NO availability, has been described The potent vasoconstrictor endothelin (ET)-1 can play [5] . Thus, endothelial ET -induced vasodilatation could no B an important pathogenic role in arterial hypertension and longer compensate for the ET -mediated vasoconstrictor A its most ominous complications, including congestive heart effect of the peptide on vascular smooth muscle cells. This failure (CHF) [1] , by exerting multiple biologic effects via contention is supported by the demonstration that the dual its type A (ET ) and B (ET ) receptors [2] . In patients (non-selective) ET and ET receptor antagonist bosentan
with essential hypertension, an increased ET-1 vasoconwas equipotent to a full dose of the ACE inhibitor enalapril strictor tone [3, 4] , which seems to be dependent on in lowering blood pressure (BP), when given orally to patients with mild-to-moderate essential hypertension [6] . Activation of the ET-1 system, which can contribute to adverse cardiovascular remodelling, has been reported in seven patients had HNRH. Patients with concomitant CHF patients who were in the New York Heart Association sicknesses that might affect the results of this investigation functional class III and IV [7] , and in pulmonary hypertenwere carefully excluded. PA was identified based on a sion, both primary [8] and secondary to CHF [9] . Thus, ET screening strategy with a logistic discriminant analysis receptor blockade is being tested as a therapeutic strategy [24] ; the underlying adrenal pathology was diagnosed with for CHF and several other cardiovascular indications [2] .
both CT or MR imaging and with adrenal vein sampling as Of interest, bosentan was shown to improve symptoms and described in detail [25] . Of the PA patients, four were functional class in patients with severe primary pulmonary untreated and two were allowed to take a long-acting hypertension [10] and therefore has been approved for the calcium entry blocker because this treatment does not treatment of this dreadful disease in some countries.
affect aldosterone and plasma renin activity (PRA) under Hyperaldosteronism appears to contribute substantively chronic conditions [26] . The predefined criterion for to the high mortality and morbidity of patients with severe selecting patients with HNRH was a PRA value greater CHF [1, 11] . ET-1 could be involved in this poor outcome than the upper limit of the normal range (0.51-2.62 ng not only because of its haemodynamic effects, but also Ang I / ml per h); three of these patients were on oral because of its potent secretagogue action on aldosterone, chronic diuretic treatment with hydrochlorothiazide (25 which occurs via a direct effect on the adrenocortical zona mg / day). These patients were selected based on the glomerulosa (ZG) [12] [13] [14] . The latter expresses the assumption that they have high-to-normal plasma aldospreproET-1 and ET converting enzyme ECE-1 genes, terone levels. along with ET and ET receptor subtypes in several
The Ethics Committee of our University approved the A B species, including humans [15] [16] [17] [18] [19] [20] and therefore ET-1 is study protocol and all patients gave written consent. likely to be an important autocrine-paracrine regulator of
To avoid any bias due to the circadian rhythm of ZG functions [21] . We found that in rat adrenocortical cells aldosterone all tests were performed at 8.30 a.m., after the ET receptor mediates the secretagogue effect of ET-1 overnight fasting and at least 2 h of quiet lying in the B [19] , but in humans in vitro studies carried out on different supine position. An indwelling cannula was placed into the adrenocortical cell phenotypes [12] [13] [14] 22] did not exclude brachial vein and a slow drip saline infusion was started the participation also of ET receptors. Thus, in humans and continued for 30 min to establish baseline values A the receptor subtype mediating the aldosterone secbefore the first blood sampling. For each sample 10 ml of retagogue action of ET-1 [13] , which can be relevant in whole blood with 100 ml 6% Na EDTA were immediately 2 pathophysiological conditions, such as CHF, malignant put on ice and centrifuged at 30003g (at 4 8C for 10 min). hypertension, primary and secondary aldosteronism, is After centrifugation, aliquots of plasma were stored at controversial. Moreover, it remains unclear whether the 220 8C until assayed. Plasma levels of sodium, potassium, haemodynamic effects of ET-1 and the relative relevance and creatinine and daily urinary excretion rate of sodium of ET -and ET selective receptor blockade differ accordand potassium were measured using conventional methods.
A B
ing to the degree of activation of the renin-angiotensin Each patient received, on different days, in random system (RAS), which deeply interacts with the ET system order and in single-blinded fashion, an infusion of either (for review, see Ref. [23] ).
BQ-123 (200 nmol / min for 5 min, followed by a 100-The development of ET and ET selective receptor nmol / min infusion for 10 min, i.v.) plus placebo, or of an
antagonists (for review, see Ref. [2] ) which can be infused identical dose of both BQ-123 and BQ-788. These low into human subjects, has made it possible to directly doses were selected based on previously studies [27] [28] [29] , investigate this issue in vivo.
in order to transiently antagonize endogenous ET-1. BQThus, in this study we investigated the acute haemo-123 and BQ-788 were purchased from Clinalfa (Laufelfidynamic effects of an infusion of the ET -selective nger, Switzerland) as sterile solution approved for injection A receptor antagonist BQ-123, either alone or associated with into human beings. Since plasma potassium levels are the ET -selective antagonist BQ-788, in hypertensive known to affect aldosterone secretion [30] , hypokalemia B patients with different degrees of RAS activation. We also was corrected in PA patients with i.v. potassium supplesought to identify the receptor subtype mediating the mentation on the day before each test, whenever required. aldosterone secretagogue effect of ET-1 and therefore
Blood sampling was performed at 215, 0, 30, 60, 120, selected patients with either primary aldosteronism (PA) or 240, 360 min for measurement of the plasma concentration high-to-normal renin hypertension (HNRH).
of aldosterone (PAC), cortisol, ACTH and PRA, while arterial blood pressure (BP) was monitored by non-invasive ambulatory BP recording (Spacelabீ, mod. 90207,
. Methods
Redmond) set to take readings every 6 min for the first 2 h and every 30 min for the last 4 h of the experiments. We enrolled for this study 13 hypertensive patients: six
We used radioimmunoassay and commercially available had PA, which was due to an aldosterone-producing kits to measure PAC (Technogenetics, Milan, Italy), cortumour in five patients and was idiopathic in one while tisol (Biochem Immunosystem, Casalecchio di Reno, 
. Results

.1. Demographic and clinical features of the patients
The main features of the patients in the two groups during clinical evaluation before entering the study are shown in Table 1 . The groups did not differ in terms of heart rate, systolic and diastolic blood pressure and serum creatinine levels. The PA patients had lower serum potassium levels and PRA, and higher PAC as compared to HNRH patients. No difference in the plasma levels of cortisol and ACTH between groups was observed. 
.2. Effects of ET receptor antagonists on BP high-to-normal renin hypertension (HNRH) (panel B). A repeated measures analysis of variance detected a significant effect of the ET-1
The patients selected for this study had moderately antagonist infusion in both groups of patients with no significant elevated BP values (Fig. 1) , as compared to the upper differences between the two infusion protocols. There were no significant changes in BP or in plasma infusion (Table 2) . PRA (Fig. 2) , ACTH and cortisol were hormones (not shown) during the placebo infusion from not significantly affected by either treatment (Table 2 ). In time 215 to time 0 on each of the 2 days of the test.
HNRH patients, both BQ-123 alone and combined with Both BQ-123 alone and combined with BQ-788 sig-BQ-788 lowered (P,0.02) aldosterone (239 and 228%, nificantly (P,0.01) lowered mean BP in both PA and respectively), the nadir being attained 30-120 min after HNRH patients (Fig. 1) . In PA patients, the nadir was the start of the infusion. Both treatments also lowered PRA reached between 51 and 81 min after the start of the significantly (243 and 216%, respectively; P,0.02) (Fig.  infusion and was 26 and 27 mmHg for BQ-123 and 2), but did not change significantly ACTH and cortisol BQ-1231BQ-788, respectively. In HNRH patients, it was plasma concentrations ( Table 2 ). reached after 51-111 min and was 210 and 26 mmHg for BQ-123 and BQ-1231BQ-788, respectively. Repeated measures ANOVA showed no differences in BP responses 4 . Discussion between BQ-123 and BQ-1231BQ-788 and no differences between PA and HNRH patients.
The detrimental effects of excess aldosterone in CHF [11] might be related to its capability to induce cardiac 3 .3. Effects of ET receptor antagonists on plasma fibrosis [33] , which can be enhanced by ET-1 [34] . In rats hormone concentrations with CHF ET receptor blockade has been shown to improve survival [35, 36] and to prevent cardiac fibrosis In PA patients, a short-lived decrease of PAC (P,0.05) and foetal gene expression more effectively than ACE was induced by combined BQ-123 and BQ-788, but not by inhibitors [37] . In patients with CHF short-term treatment BQ-123 alone (Fig. 2) . With combined BQ-123 and BQwith ET receptor antagonists was consistently found to 788 the nadir was attained 60 min after the start of the exert favourable haemodynamic effects [38, 39] , but to date the results of clinical trials have not fulfilled the promises that this anti-hypertensive effect of ET receptor antagonists of this therapeutic strategy (for review, see Ref. [40] ).
was associated with changes in PAC, which occurred with The variable effects of selective and non-selective ET different mechanisms in patients with PA and HNRH. receptor blockade on neuro-hormonal activation in the Thus, endogenous ET-1 does play a role in regulating BP different species might account for these results. Accordand the plasma level of aldosterone in hypertensive ingly, in this study we sought to identify the effects on BP patients with a suppressed RAS due to excess autonomous and the ET receptor subtype that mediates aldosterone aldosterone secretion and with HNRH. secretion in hypertensive patients by administering for a To our knowledge this lowering of BP with acute ET short period of time a low dose of the ET -selective receptor antagonist administration is the first ever obtained blockade in a head-to-head comparison of BQ-123 and pertensive patients [6] and in different models of hyperten-BQ-788, because experience with both angiotensin II type sion, as well as with findings in normotensive subjects 1 (AT-1) and type 2 (AT-2) receptor antagonists and with [41] . Furthermore, it supports the contention that the ET-1 ET receptor antagonists consistently showed that blockade system is activated in mineralocorticoid-dependent forms of a single receptor subtype resulted in enhanced activation of hypertension, both in humans [43] and in animals [44] . of the other. In fact, in human healthy volunteers the By selecting hypertensive patients with different degrees infusion of ET-1 on top of BQ-123 resulted in paradoxical of activation of the RAS we could distinguish the effects vasodilatation in the forearm vascular bed, which indicated of ET-1 resulting from an interaction of the peptide with enhanced activation of the ET -mediated NO production the RAS from those occurring directly at the adrenal cortex less straightforward interpretation of results would have activated RAS, the PAC were decreased by both BQ-123 been derived. alone and combined with BQ-788, thereby indicating that We selected hypertensive patients with contrasting levels when the RAS is up-regulated, the lowering of aldosterone of PRA to verify whether the receptor subtype mediating may occur through an ET -mediated blunting of renin A this important biological effect of ET-1 differed depending secretion. This contention is supported by studies in dogs, on the prevailing degree of activation of the RAS. We which indicated that exogenous ET-1 increases PRA [45] found that the ET -selective blockade, either alone or and that this effect might be blunted by the ET -selective lowering of BP that is consistent with the previous reports These conclusions have relevant implications for the of vasodilatation in hypertensive patients [3, 4] . development of ET antagonists in the treatment of other More importantly, our results showed for the first time conditions, including CHF. In CHF patients, as well as in It has to be stressed that our study has some limitations, patients with chronic congestive heart failure. Circulation
